Background: The systemic immune-inflammation index (SII) has been reported to be associated with patient survival in various kinds of solid tumors. However, just few studies have focused on its prognostic value in patients with surgically resected esophageal squamous cell carcinoma (ESCC). Materials and Methods: This study was a single-institution, retrospective analysis of 468 ESCC patients who underwent curative esophagectomy at the Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College between 2005 and 2008. The receiver operating curve (ROC) was plotted to compare the discrimination ability of the SII and other inflammatory factors for overall survival (OS) and disease-free survival (DFS). Univariate and multivariate analyses were performed based on the Cox proportional hazards regression model. Results: The SII, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) were all associated with OS in ESCC patients. The SII, NLR, and PLR were independent prognostic factors for OS (hazard ratio (HR) = 1.604, 95% confidence interval (CI) 1.247-2.063, P < 0.001; HR = 1.396, 95% CI 1.074-1.815, P = 0.013; HR = 1.370, 95% CI 1.067-1.758, P = 0.013, respectively) and DFS (HR = 1.681, 95% CI 1.307-2.162, P < 0.001; HR = 1.376, 95% CI 1.059-1.788, P = 0.017; HR = 1.398, 95% CI 1.089-1.794, P = 0.009, respectively). The area under the curve (AUC) for SII was bigger than NLR, PLR, and MLR (0.553, 0.540, 0.532, and 0.521, respectively). Conclusion: The SII is a simple and promising prognostic predictor for patients with surgically resected ESCC. The prognostic value of SII is superior to those of the NLR, PLR and MLR. Moreover, the SII retained prognostic significance in stage I-II ESCC subgroup (OS, DFS) and stage III ESCC subgroup (DFS).
Introduction
Esophageal cancer (EC) is currently the fifth most commonly diagnosed malignancy and the fourth leading cause of cancer deaths in China [1] . Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) constitute two major histological types of EC. ESCC is the most common histological type in Chinese patients, accounting for 90% of all cases, whereas EAC is Ivyspring International Publisher predominant in many western countries [2] . So far, the standard care for ESCC patients is curative esophagectomy, with or without chemoradiation therapy. Unfortunately, ESCC patients still show a poor five-year survival rate of <30%, even after curative therapy and eventually developing rapid clinical progression [3, 4] .Therefore, it is imperative to evaluate better prognostic factors, particularly serum predictive indicators, in ESCC patients.
Recent studies have demonstrated that a preoperative inflammatory response could be associated with tumor progression and metastasis and have a significant predictive and prognostic value in various types of cancers [5] [6] [7] [8] . There is increasing recognition that the NLR, PLR, and MLR are three markers of systemic inflammation and the elevated values of them might lead to a poor prognosis in various solid tumors, including ESCC [9] [10] [11] [12] . However, these three inflammatory factors only integrate two cells. SII, which based on peripheral neutrophil, platelet, and lymphocyte counts, was recently investigated as a novel prognostic marker [13] [14] [15] [16] . And to our best knowledge, just few studies regarding SII in patients with surgically resected ESCC are available. Thus, we conducted the present study to investigate and verify the prognostic value of the SII for a larger cohort of patients with surgically resected ESCC.
Materials and Methods

Patients
We retrospectively reviewed a database of medical records of 530 consecutive patients with surgically resected ESCC between 2005 and 2008 at the department of thoracic surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College. The inclusion criteria were as follows: (1) curative esophagectomy with R0 resection; (2) histologically confirmed ESCC; 3) preoperative serum laboratory results were obtained within five days before surgery. The exclusion criteria were as follows: (1) if patients received preoperative chemotherapy/radiotherapy; (2) if they had acute/chronic infection or (3) if they had hematological or autoimmune disease; (4) if they died during the perioperative period; (5) if they lacked detailed clinical information and follow-up information. Totally, 62 patients were excluded from this study. The whole enrollment process was clearly shown in Figure 1 . Among these patients, 15 patients had infection, hematological or autoimmune disease; 12 patients had incomplete medical data; and 35 patients were lost to follow-up. Finally, a total of 468 patients were enrolled in the present study.
All included subjects provided written informed consent for the study protocol that was approved by the Ethical Committees of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College. Patients were followed up in the outpatient department every 3-6 months for the first two years after surgery and then annually. The follow-up included recording the medical history, physical examinations, chest computed tomography, and endoscopy (if necessary). The last follow-up was on July 9 th 2015. And in our study, the primary endpoints were 5-year OS and 5-year DFS.
Clinicopathological parameters
The clinicopathological parameters of the patients, including age, gender, smoking history, drinking history, tumor location, tumor differentiation grade, maximum tumor diameter, lymph node metastasis, TNM stage, operation time, and intraoperative blood loss, were obtained from the medical records. The pathological classification of the primary tumor, degree of lymph node metastasis, and presence of distant metastasis were assessed based on the American Joint Committee on Cancer staging manual (seventh edition) [17] . 
Blood sample analysis
The laboratory data on preoperative CBC counts were retrospectively extracted from medical records. All these results were obtained within five days before surgery. CBC was measured using EDTA-treated blood and analyzed using an automated hematology analyzer XE-2100 (SYSMEX hematology analyzer; Medical Electronics, Kobe, Japan).
SII, NLR, PLR, and LMR evaluations
Data on preoperative blood cell counts were retrospectively extracted from the medical records. White blood cell count data were analyzed in the general routine laboratory of our hospital within one week before surgery. We calculated the SII, NLR, PLR and MLR as follows: SII = platelet counts × neutrophil counts/lymphocyte counts, NLR = neutrophil counts/lymphocyte counts, PLR = platelet counts/lymphocyte counts, MLR = monocyte counts/lymphocyte counts.
Statistical analysis
We used SPSS version 19.0 (IBM Corp., Armonk, NY, USA) to perform all statistical analyses. The Pearson Chi-square test was used to compare categorical variables. Multiple linear regression analyses were used to determine factors associated with SII, NLR, PLR, and MLR. We constructed the Receiver operated characteristics (ROC) curves to determine the cut-off values for SII, NLR, PLR, and MLR that yielded the joint maximum sensitivity and specificity. The Kaplan-Meier method was used for univariate analysis, and the difference between groups was assessed by the log-rank test. The Cox proportional hazard model was used for multivariate analysis, and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to quantify the strength of the association between predictors and survival. A two-sided value of P < 0.05 was considered statistically significant.
Results
Patients characteristics
The 468 patients in this study were 376 (80.3%) men and 92 (19.7%) women ( 
Selection of optimal cut-off values for SII, NLR, PLR and MLR
As shown in Figure 2 , the AUC was 0.553, 0.540, 0.532, and 0.521 for SII, NLR, PLR, and MLR, respectively. The optimal cut-off values for the prediction of survival were 479.72 for SII, 2.27 for NLR, 117.07 for PLR and 0.19 for MLR. Consequently, patients were separately divided into two groups with high or low levels according to the optimal cut-off values. One hundred and forty-three patients (30.6%) had SII ≥ 479.72, 127 patients (27.1%) had NLR ≥ 2.27, 153 patients (32.7%) had PLR ≥ 117.07 and 165 (35.3%) patients had MLR ≥0.19. 
Correlation between the clinicopathological parameters and SII, NLR, PLR, and MLR
The relationship between the clinicopathological parameters and SII is shown in Table 1 . The preoperative SII were associated with gender (p = 0.005) and more intraoperative blood loss (p = 0.044) ( Table 1) .
The relationship between the clinicopathological parameters and NLR, PLR, and MLR is shown in Table 2 . The preoperative NLR were associated with gender (p = 0.005), tumor length (p = 0.020), and T stage (p=0.010). The preoperative MLR were associated with tumor length (p = 0.010) and T stage (p=0.024) ( Table 2 ).
The prognostic value of SII, NLR, PLR, and MLR
OS curves were plotted by the Kaplan-Meier method and compared using the log-rank test. High SII, NLR, PLR and MLR were associated with poor OS (p = 0.001, p = 0.033, and p = 0.027, respectively) ( Figure 3A-3C ) and poor DFS (p < 0.001, p = 0.034, and p = 0.024, respectively) ( Figure 4A-4C) . However, no significant differences were found between MLR and patients' OS (p = 0.104) ( Figure 3D ) and DFS (p = 0.093) ( Figure 4D ). 
Univariate and multivariate analyses
Univariate analyses demonstrated that age, smoking history, T stage, lymph node metastasis, TNM stage, operation time, intraoperative blood loss, SII, NLR, PLR were significant risk factors for a poor prognosis for OS and DFS (Table 3) . To avoid multicollinearity, we conducted the multivariate analysis using four models separately. Each multivariate model included only one immune-inflammatory indicator (SII, NLR, PLR, or MLR). The results revealed age (P < 0.001), TNM stage (P < 0.001), operation time (P = 0.030), high SII levels (P = 0.001), high NLR (P = 0.013) and high PLR (P = 0.013) were found to be independently associated with a poor OS or DFS in the multivariate analysis (Table 4 ). * P less than 0.05 is significant. CI = confidence interval; OS = overall survival; HR = hazard ratio; SII = systemic immune-inflammation index; NLR = neutrophil-lymphocyte ratio; PLR = platelet-lymphocyte ratio; MLR = monocyte-lymphocyte ratio * P less than 0.05 is significant. CI = confidence interval; OS = overall survival; HR = hazard ratio; SII = systemic immune-inflammation index; NLR = neutrophil-lymphocyte ratio; PLR = platelet-lymphocyte ratio; MLR = monocyte-lymphocyte ratio 
Discussion
In recent years, increasing evidence demonstrated that there is a strong association between systemic inflammation and cancer [18] [19] [20] . In the present study, we retrospectively analyzed a consecutive cohort of 468 ESCC patients who underwent curative esophagectomy with R0 resection in our center. To our best knowledge, the population size and the quality of follow-up of the present study were much better than other two similar studies [21, 22] . It was worth mentioning that our study focused on the prognostic value of the SII for both OS and DFS of the ESCC patients. Our result showed that a high SII was an independent predictor for both OS and DFS in patients with surgically resected ESCC, and by comparing the areas under the AUC curve, SII was superior to NLR, PLR, and MLR in terms of prognostic ability. We also found that high SII was associated with gender and intraoperative blood loss. Moreover, we divided the 468 patients into two different groups according to their TNM stage for further analysis. The subgroup results showed that SII retained prognostic significance in stage I-II ESCC subgroup (OS, DFS) and stage III ESCC subgroup (DFS).
Systemic inflammatory factors such as NLR, PLR and MLR have been found to be independent markers of prognosis in a variety of cancers, including ESCC [23] [24] [25] [26] [27] . Feng [24] et al. revealed that preoperative NLR and PLR were significant predictors of OS in patients with ESCC and that PLR was superior to NLR as a prognostic index. Nakamura et al. [25] and Yutong et al. [26] have suggested that an increased NLR is associated with tumor progression and poor survival in EC patients. Recently, a meta-analysis by Zhao et al. [28] showed that a higher PLR might be a significant predictive biomarker for EC patients. Hirahara et al. [23, 27] also demonstrated that a decreased LMR was an independent prognostic factor for OS in ESCC patients. SII, based on neutrophil, platelet, and lymphocyte counts, was shown to be an independent prognostic indicator for hepatocellular carcinoma, lung cancer, colorectal cancer, renal cancer, prostate cancer and gastric cancer patients [12, 13, 15, [29] [30] [31] .
The mechanism by which high SII contributes to a poor prognosis in patients with solid cancer is still unclear. Several potential theories may be used to explain the prognostic values of SII. Firstly, neutrophils expand both in the tumor microenvironment and systemically, and are generally associated with poor prognosis in patients with solid cancers [32] . Neutrophils may activate endothelium and parenchymal cells to enhance circulating tumor cell adhesion for distant metastasis [33] . Neutrophilia is an inflammatory response that inhibits the immune system by suppressing the cytolytic activity of immune cells such as lymphocytes, activated T cells, and natural killer cells [34, 35] . Secondly, platelets may act as protective "cloaks" for circulating tumor cells (CTCs), shielding them from immune destruction. Platelet and endothelial cell adhesion proteins may also facilitate metastasis by augmenting tumor cell extravasation [36] . Thirdly, the importance of lymphocytes has been highlighted in several studies in which high TILs (tumor-infiltrating lymphocytes) has been associated with better response to cytotoxic treatment and prognosis in cancer patients [37, 38] . Lymphocytes can also secrete several cytokines, such as IFN-γ and TNF-α, to block tumor growth and improve the prognosis of cancer patients [39] . According to the above theories, SII should be a more objective marker that reflects the balance between host inflammatory and immune response status than all the other systemic inflammation indices such as NLR, PLR and MLR.
Our study had several limitations. First, our study may be limited by selection biases due to its single-centre, retrospective nature. Second, although our results showed that SII was an independent predictor of ESCC prognosis, the sensitivity and specificity of SII were not very high. Third, although our findings were in line with previous observations, it was not easy to verify our conclusions in another independent cohort due to the lack of standardized cutoff value for SII. The cutoff values for SII were different among these similar studies [21, 22, 40, 41] . So, we need perspective studies to find a proper cutoff value. Thus, multi-center collaborative prospective studies are warranted to confirm these preliminary results.
Conclusions
The SII is an independent prognostic marker in patients with surgically resected ESCC, and the SII is superior to NLR, PLR and MLR in terms of prognostic ability. Moreover, SII retained prognostic significance in stage I-II ESCC subgroup (OS, DFS) and stage III ESCC subgroup (DFS).
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